<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653417</url>
  </required_header>
  <id_info>
    <org_study_id>VMRAD1901-203</org_study_id>
    <nct_id>NCT02653417</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical safety of and whether RAD1901 reduces
      the frequency and severity of VMS in postmenopausal women regardless of uterine status.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objectives of this study are to determine the safety and efficacy of RAD1901 in postmenopausal women with moderate to severe VMS as assessed by a reduction from baseline in the frequency and severity of hot flashes</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the severity of hot flashes at 4 and 12 weeks</measure>
    <time_frame>4 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the frequency of moderate to severe hot flashes at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the frequency of mild, moderate, and severe hot flashes at 4 and 12 weeks by eDiary</measure>
    <time_frame>4 and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD1901 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD1901 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD1901 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD1901</intervention_name>
    <description>RAD1901</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Regimen 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To participate in this study, a subject MUST:

          1. be a postmenopausal woman between 40 and 65 years of age, inclusive

          2. be seeking relief or treatment for moderate to severe VMS

          3. be willing to discontinue and abstain from the following: vaginal hormonal products;
             transdermal or oral estrogen or estrogen/progestin combination; progestin implants;
             injectable estrogen; topical progesterone cream, selective estrogen receptor
             modulators [e.g., ospemifene, raloxifene, tamoxifen, DuaveeÂ® (conjugated estrogens and
             bazedoxifene) and intrauterine devices (IUDs)]

          4. have a normal or clinically insignificant transvaginal ultrasound (TVU)

          5. have a normal endometrial biopsy subsequent to the TVU without clinically relevant
             results

          6. have a normal screening Papanicolaou (Pap) smear

          7. have a mammogram within 9 months prior to randomization. Subjects must have a Breast
             Imaging Reporting and Data System (BI-RADS) mammography result of 1 or 2 to enroll.

        Exclusion Criteria:

        Subjects with any of the following characteristics will not be eligible to participate in
        the study:

          1. have a history of invasive breast cancer or ductal carcinoma in situ, melanoma or any
             gynecologic cancer.

          2. using any of the following:

               -  oral estrogen-, progestin-, androgen-, or selective estrogen receptor modulator
                  containing drug products within 8 weeks before screening (visit 1)

               -  transdermal hormone products within 4 weeks before screening (visit 1)

               -  vaginal hormone products (rings, creams, gels) within 4 weeks before screening
                  (visit 1)

               -  progestin implants/injectables, IUDs or estrogen pellets/injectables within 6
                  months before screening (visit 1)

               -  anabolic steroids

          3. have been treated with a GnRH agonist within the last year

          4. have been treated with anti-estrogens, or aromatase inhibitors within 2 months prior
             to study entry

          5. have been concurrently treated and will abstain from gabapentin and paroxetine or
             serotonin and norepinephrine reuptake inhibitors (SNRIs) for VMS or other indications
             for 3 months during the trial and have not taken within 4 weeks prior to screening

          6. have an endometrial biopsy at baseline with a diagnosis by a gynecologic pathologist
             of proliferative, hyperplasia, polyp or cancer

          7. unresolved findings suspicious for malignancy on the breast examination
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women's Health Care Specialists P.C. - Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

